Full Year Trading Update
31/01/2025 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250131:nRSe3685Va&default-theme=true
RNS Number : 3685V Alliance Pharma PLC 31 January 2025
For immediate release 31 January 2025
ALLIANCE PHARMA
("Alliance", "Company" or the "Group")
Full Year Trading Update
Alliance Pharma plc (AIM: APH), the international healthcare group, announces
its unaudited trading update for the year ended 31 December 2024 (the
"Period"), ahead of the announcement of the Group's audited results.
The Group delivered see-through(1) revenues in the Period of £180.3m (FY23:
£182.7m), down 1% versus the prior period and up 1% at constant exchange
rates ("CER"). Whilst revenues declined in some of our brands, we delivered
strong performance in Kelo-Cote, MacuShield, Hydromol and Forceval.
Kelo-Cote franchise revenues grew 6% CER to £65.4m (FY23: £63.2m) in-line
with previous guidance of mid-single digit revenue growth. Whilst we remain
committed to moving to smaller, more regular orders in China, this is taking
longer than we anticipated. Nizoral revenues declined 21% CER to £16.4m
(FY23: £21.7m) due to the timing of distributor orders. Amberen revenues
declined 7% CER to £10.1m (FY23: £11.2m). Other Consumer declined 2% CER to
£38.8m (FY23: £40.3m) with a strong performance in MacuShield (+11% CER)
offset by weakness in Lefuzhi and Ashton & Parsons. Consequently, total
see-through Consumer Healthcare revenues declined 2% CER to £130.7m (FY23:
£136.4m).
Prescription Medicine revenues increased 8% CER to £49.6m (FY23: £46.3m).
Forceval delivered another solid performance with revenues up 20% CER to
£7.9m (FY23: £6.6m), Hydromol revenues increased 14% CER to £10.3m (FY23:
£9.0m) and other prescription medicine revenues showed strong recovery as
previously out of stock products became available.
The Board continues to anticipate that underlying Group profit in FY 2024 will
be in line with FY 2023.
Nick Sedgwick, Chief Executive Officer of Alliance, commented:
"I am pleased that performance in 2024 is in-line with expectations. Whilst we
have much to do as we work on our transformation plans, I am confident that
our strong portfolio of clinically differentiated brands will deliver
predictable organic revenue growth over the mid-long term."
(1) See-through revenue includes sales from Nizoral as if they had been
invoiced by Alliance as principal. For statutory accounting purposes the
product margin relating to Nizoral sales made on an agency basis is included
within Revenue, in line with IFRS 15.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications + 44 (0)1249 705168
ir@allianceph.com (mailto:ir@allianceph.com)
Burson Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills
alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)
Deutsche Numis (Nominated Adviser and Joint Broker) + 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher Shah
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our
purpose is to empower people to make a positive difference to their health and
wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and
channels, in related innovation, and through selective geographic expansion to
increase the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics we remain asset-light and focused
on maximising the value we can bring, both to our stakeholders and to our
brands.
For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TSTFFFSLLTIIVIE